logo

For the Inventor, By the Inventor

Manchester, United Kingdom

Redx Pharma Limited


USPTO Granted Patents = 27

% Expired Patents = 44.4



Forward Citations = 74

Loading Chart...
Loading Chart...

39 inventors (with patents filed for the assignee):

goldMedal Inder Bhamra (10 out of 11 patents)

silverMedal Richard Testar (8 out of 9 patents)

bronzeMedal Craig Donoghue (7 out of 7 patents)

4.  Matilda Bingham (6 out of 7 patents)

5.  David John Moody (6 out of 7 patents)

6.  Jonathan William Wiffen (6 out of 6 patents)

7.  Louise Sargent (4 out of 4 patents)

8.  Derek Lindsay (4 out of 5 patents)

9.  Clifford David Jones (4 out of 16 patents)

10.  Michael Mathieson (3 out of 3 patents)

11.  Peter Jackson (3 out of 4 patents)

12.  Thomas Pesnot (3 out of 5 patents)

13.  Peter Bunyard (3 out of 3 patents)

14.  Gary Pitt (3 out of 3 patents)

15.  Liam Byrne (3 out of 3 patents)


Core Competencies:
DDR1 Inhibitors
Rho-Associated Protein Kinase
Wnt Signaling Pathway
Antibacterial Compounds
Fused Bicyclic Compounds
Hedgehog Signaling Pathway
Rosuvastatin Derivatives
Triazolo-Pyrazines
Redox Drug Derivatives
Pyridine Derivatives
Statin Preparation
Heterocyclic Compounds

27 patents:

1. 12692247 - Phenyl- and pyridopyrazole derivatives as inhibitors of DDR1 (2026-07-28),
2. 12453734 - Modulators of rho-associated protein kinase (2025-10-28),
3. 12202826 - N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway (2025-01-21),
4. 11878020 - Modulators of Rho-associated protein kinase (2024-01-23),
5. 11643408 - N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway (2023-05-09),
6. 11497751 - Modulators of Rho-associated protein kinase (2022-11-15),
7. 11459326 - N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors (2022-10-04),
8. 10793562 - N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors (2020-10-06),
9. 10793560 - N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway (2020-10-06),
10. 10487093 - Heterocyclic compounds, in particular 2-oxo-4,4,5,5,6,6,7,7-octahydrobenzoxazole derivatives, and their use as antibacterial compounds (2019-11-26),
11. 10385065 - Antibacterial compounds (2019-08-20),
12. 10202375 - N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors (2019-02-12),
13. 10183939 - Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers (2019-01-22),
14. 10047079 - N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway (2018-08-14),
15. 9850234 - Pyridine derivatives as soft rock inhibitors (2017-12-26),
Redx Pharma Limited, based in Manchester, specializes in the discovery and development of innovative drug candidates targeting unmet medical needs. The company focuses on areas such as oncology and anti-infectives, leveraging its expertise in medicinal chemistry and drug development. Redx Pharma aims to advance its proprietary compounds through various stages of clinical development, contributing to the pharmaceutical landscape with a commitment to improving patient outcomes and addressing critical health challenges.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Redx Pharma Limited
27 Patents

#10 in Manchester

#655 in United Kingdom

#23,968 in the World

Manchester, GB
Manchester, United Kingdom

Redx Pharma Limited

Forward Citations = 74

39 inventors:

goldMedal Inder Bhamra (10 out of 11 patents)

silverMedal Richard Testar (8 out of 9 patents)

bronzeMedal Craig Donoghue (7 out of 7 patents)

4.  Matilda Bingham (6 out of 7 patents)

5.  David John Moody (6 out of 7 patents)

Please report any incorrect information to [email protected]
Loading…